Mereo BioPharma (MREO) Gains from Investment Securities (2021 - 2026)
Mereo BioPharma (MREO) reported Gains from Investment Securities of $268211.0 for Q1 2026, up 164.47% year-over-year from $101413.1 in Q1 2025, and up 191.23% quarter-over-quarter from -$294000.0 in Q4 2025.
Mereo BioPharma (MREO) Gains from Investment Securities (2021 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has 6 years of Gains from Investment Securities data on file, last reported at $268211.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $268211.0, up 164.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $268211.0 (up 111.65% YoY), and the FY2025 annual result was $458375.0, down 70.28% from the prior year.
- Gains from Investment Securities advanced to $268211.0 in Q1 2026 per MREO's latest filing, from -$294000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $2.0 million in Q2 2025 and troughed at -$2.3 million in Q4 2024.
- A 5-year average of $172296.9 and a median of $125393.0 in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities sank 628.64% in 2024, then soared 1480.7% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $2.0 million in 2022, then slumped by 77.72% to $440000.0 in 2023, then slumped by 628.64% to -$2.3 million in 2024, then surged by 87.36% to -$294000.0 in 2025, then surged by 191.23% to $268211.0 in 2026.
- Business Quant data shows MREO's Gains from Investment Securities at $268211.0 in Q1 2026, -$294000.0 in Q4 2025, and $124233.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mereo BioPharma | 252.49 Mn | 252.49 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 268,211.00 |
| Mar 31, 2026 | 268,211.00 |
| Dec 31, 2025 | -294,000.00 |
| Dec 31, 2025 | -294,000.00 |
| Sep 30, 2025 | 124,233.00 |
| Sep 30, 2025 | 124,233.00 |
| Jun 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | -416,000.00 |
| Mar 31, 2025 | -416,000.00 |
| Dec 31, 2024 | -2.33 Mn |
| Dec 31, 2024 | -2.33 Mn |
| Sep 30, 2024 | 441,247.00 |
| Sep 30, 2024 | 441,247.00 |
| Jun 30, 2024 | 125,393.00 |
| Jun 30, 2024 | 125,393.00 |
| Mar 31, 2024 | 360,000.00 |
| Mar 31, 2024 | 360,000.00 |
| Dec 31, 2023 | 440,000.00 |
| Dec 31, 2023 | 440,000.00 |